[go: up one dir, main page]

WO2010066901A3 - Composés de tétrahydrotriazine pour le traitement de maladies associées à une activité ampk - Google Patents

Composés de tétrahydrotriazine pour le traitement de maladies associées à une activité ampk Download PDF

Info

Publication number
WO2010066901A3
WO2010066901A3 PCT/EP2009/066999 EP2009066999W WO2010066901A3 WO 2010066901 A3 WO2010066901 A3 WO 2010066901A3 EP 2009066999 W EP2009066999 W EP 2009066999W WO 2010066901 A3 WO2010066901 A3 WO 2010066901A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
diseases associated
treating diseases
podocytopathy
ampk activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/066999
Other languages
English (en)
Other versions
WO2010066901A2 (fr
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Didier Mesangeau
Samer Elbawab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09799313.3T priority Critical patent/ES2573266T3/es
Priority to EP09799313.3A priority patent/EP2367802B1/fr
Priority to MX2011005644A priority patent/MX2011005644A/es
Priority to JP2011540126A priority patent/JP5485292B2/ja
Priority to BRPI0922650A priority patent/BRPI0922650A2/pt
Priority to CN2009801499067A priority patent/CN102245581A/zh
Priority to CA2745854A priority patent/CA2745854A1/fr
Priority to AU2009326965A priority patent/AU2009326965A1/en
Application filed by Poxel SA filed Critical Poxel SA
Priority to US12/998,848 priority patent/US9035048B2/en
Publication of WO2010066901A2 publication Critical patent/WO2010066901A2/fr
Publication of WO2010066901A3 publication Critical patent/WO2010066901A3/fr
Priority to IL212901A priority patent/IL212901A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (I), dans laquelle les radicaux R1 à R6 ont la signification telle que définie dans la revendication 1, et/ou des sels physiologiquement acceptables de ces composés, destinés au traitement prophylactique ou thérapeutique et/ou à la surveillance de troubles physiologiques et/ou pathologiques qui sont associés à l'activité de la protéine kinase activée par l'AMP (AMPK). Un autre objet de l'invention concerne l'utilisation desdits composés pour augmenter l'homéostasie glucidique, réduire une podocytose et/ou diminuer la production d'espèces réactives de l'oxygène (ROS). L'invention concerne également une méthode de diagnostic in vitro d'une néphropathie diabétique et un procédé de criblage de composés qui réduisent une podocytose, dans chaque cas en faisant intervenir de la synaptopodine en tant que biomarqueur.
PCT/EP2009/066999 2008-12-12 2009-12-11 Composés de tétrahydrotriazine pour le traitement de maladies associées à une activité ampk Ceased WO2010066901A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2745854A CA2745854A1 (fr) 2008-12-12 2009-12-11 Composes de tetrahydrotriazine pour le traitement de maladies associees a une activite ampk
MX2011005644A MX2011005644A (es) 2008-12-12 2009-12-11 Compuestos de tetrahidrotriazina para tratar enfermedades asociadas con la actividad de ampk.
JP2011540126A JP5485292B2 (ja) 2008-12-12 2009-12-11 Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
BRPI0922650A BRPI0922650A2 (pt) 2008-12-12 2009-12-11 Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
CN2009801499067A CN102245581A (zh) 2008-12-12 2009-12-11 用于治疗与ampk活性有关的疾病的四氢三嗪化合物
ES09799313.3T ES2573266T3 (es) 2008-12-12 2009-12-11 Compuestos de tetrahidrotriazina para tratar enfermedades relacionadas con la actividad de AMPK
EP09799313.3A EP2367802B1 (fr) 2008-12-12 2009-12-11 Composés de tétrahydrotriazine pour le traitement de maladies associées à une activité ampk
AU2009326965A AU2009326965A1 (en) 2008-12-12 2009-12-11 Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
US12/998,848 US9035048B2 (en) 2008-12-12 2009-12-11 Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
IL212901A IL212901A0 (en) 2008-12-12 2011-05-16 Tetrahydrotriazine compounds for treating diseases associated with ampk activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08021618.7 2008-12-12
EP08021618 2008-12-12

Publications (2)

Publication Number Publication Date
WO2010066901A2 WO2010066901A2 (fr) 2010-06-17
WO2010066901A3 true WO2010066901A3 (fr) 2010-08-05

Family

ID=42026760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/066999 Ceased WO2010066901A2 (fr) 2008-12-12 2009-12-11 Composés de tétrahydrotriazine pour le traitement de maladies associées à une activité ampk

Country Status (12)

Country Link
US (1) US9035048B2 (fr)
EP (1) EP2367802B1 (fr)
JP (1) JP5485292B2 (fr)
CN (1) CN102245581A (fr)
AU (1) AU2009326965A1 (fr)
BR (1) BRPI0922650A2 (fr)
CA (1) CA2745854A1 (fr)
ES (1) ES2573266T3 (fr)
IL (1) IL212901A0 (fr)
MX (1) MX2011005644A (fr)
TW (1) TW201033182A (fr)
WO (1) WO2010066901A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104611421B (zh) 2008-08-12 2018-08-07 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
US9271984B2 (en) * 2010-06-09 2016-03-01 Poxel Treatment of type 1 diabetes
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
ES2834986T3 (es) 2011-01-07 2021-06-21 Anji Pharma Us Llc Terapias basadas en ligandos de receptores quimiosensoriales
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
NZ626578A (en) * 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2018079855A1 (fr) * 2016-10-31 2018-05-03 国立大学法人京都大学 Composition de médicament destinée à induire dans des cellules cancéreuses une mort cellulaire programmée
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
WO2019069230A1 (fr) 2017-10-02 2019-04-11 Poxel Méthodes de traitement d'une insuffisance cardiaque avec fraction d'éjection préservée
CN111918655B (zh) * 2018-06-06 2024-05-31 博希尔公司 治疗患有慢性肾脏疾病的糖尿病受试者的方法
KR20210003786A (ko) 2018-06-14 2021-01-12 폭셀 당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정
EP4153589A4 (fr) 2020-05-19 2024-06-12 Kallyope, Inc. Activateurs d'ampk
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079916A2 (fr) * 2006-01-13 2007-07-19 Merck Patent Gmbh Combinaison de derives de triazine et d'inhibiteurs de l'hmg-coa reductase
WO2007079917A2 (fr) * 2006-01-13 2007-07-19 Merck Patent Gmbh Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline
DE60121294T2 (de) * 2000-01-26 2007-08-30 Merck Santé Dihydro-1,3,5-triazinaminderivate und ihre therapeutischen verwendungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629467A (en) * 1969-10-17 1971-12-21 Armour Pharma Pharmaceutical preparations containing a 2 4-diamino-6-substituted-s-triazine and methods of using same
WO1991001733A1 (fr) * 1989-08-09 1991-02-21 Nippon Shinyaku Co., Ltd. Remede
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
WO2005030735A1 (fr) * 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Derives de triazines comme inhibiteurs de l'adhesion cellulaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60121294T2 (de) * 2000-01-26 2007-08-30 Merck Santé Dihydro-1,3,5-triazinaminderivate und ihre therapeutischen verwendungen
WO2007079916A2 (fr) * 2006-01-13 2007-07-19 Merck Patent Gmbh Combinaison de derives de triazine et d'inhibiteurs de l'hmg-coa reductase
WO2007079917A2 (fr) * 2006-01-13 2007-07-19 Merck Patent Gmbh Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline

Also Published As

Publication number Publication date
MX2011005644A (es) 2011-06-16
BRPI0922650A2 (pt) 2017-07-11
US20110236317A1 (en) 2011-09-29
TW201033182A (en) 2010-09-16
EP2367802A2 (fr) 2011-09-28
CN102245581A (zh) 2011-11-16
ES2573266T3 (es) 2016-06-06
EP2367802B1 (fr) 2016-04-20
CA2745854A1 (fr) 2010-06-17
US9035048B2 (en) 2015-05-19
JP5485292B2 (ja) 2014-05-07
AU2009326965A1 (en) 2011-06-23
JP2012511549A (ja) 2012-05-24
WO2010066901A2 (fr) 2010-06-17
IL212901A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
WO2010066901A3 (fr) Composés de tétrahydrotriazine pour le traitement de maladies associées à une activité ampk
WO2008144591A3 (fr) Traitement de synucléinopathies
WO2005116003A3 (fr) Derives de dioxyde de benzisothiazole-oxazole substitues, procede de production desdits derives et leur utilisation
WO2009036082A3 (fr) Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation
WO2009151598A8 (fr) Diazacarbazoles et procédés d’utilisation
WO2008156869A3 (fr) Composés modulant les sirtuines
WO2009100131A3 (fr) Processus pour diagnostiquer ou traiter les lésions cérébrales
NO20092651L (no) Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
WO2009042435A8 (fr) Activateurs de glucokinase
WO2009030224A3 (fr) Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale
Desrosiers Participation and occupation.
WO2009033561A8 (fr) Acides 6-phénylnicotiniques substitués et leur utilisation
WO2009018478A3 (fr) Utilisation d'essais génomiques et de composés cétogéniques pour le traitement d'une fonction cognitive réduite
WO2010063701A3 (fr) Procédé d'imagerie in vivo
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
IL188827A0 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2010124240A3 (fr) Bin1 comme marqueur de pronostic dans une maladie cardiovasculaire
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
WO2010037042A3 (fr) Procédés pour détecter et traiter le cancer
WO2009064927A3 (fr) Acide gras synthase phosphoryle et traitement du cancer
WO2010148121A3 (fr) Dérivés de benzothiazole
WO2007112355A3 (fr) Procédés utilisant de l'hémoglobine pour la prophylaxie, le diagnostic et/ou le traitement de troubles de la rétine
WO2013106766A3 (fr) Indications thérapeutiques du miarn-1291
WO2011045383A3 (fr) Composés 2,6 diaminopyridines appropriés pour le traitement de maladies associées aux protéines amyloïdes ou de type amyloïde pour le traitement ou la prévention de maladies ou d'états oculaires associés à une anomalie/changement pathologique dans le tissu du système visuel
WO2008031501A3 (fr) Nouveaux dérivés d'acide 2-phénoxynicotinique et leur utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980149906.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09799313

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 212901

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005644

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2745854

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4336/DELNP/2011

Country of ref document: IN

Ref document number: 12998848

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011540126

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009326965

Country of ref document: AU

Date of ref document: 20091211

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009799313

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0922650

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110608